Have an account? Log in.
I don't have an account.
Cantor Fitzgerald suspends Neutral rating on Soleno Therapeutics (NASDAQ:SLNO).
Wells Fargo analyst Derek Archila downgrades Soleno Therapeutics (NASDAQ:SLNO) from Overweight to Equal-Weight and lowers the price target from $110 to $53.
Top Wall Street analysts changed outlook on top names. Check analyst ratings page for complete view. Consider buying SLNO stock, see analysts' views.
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Soleno Therapeutics (NASDAQ:SLNO) from Buy to Neutral and lowers the price target from $100 to $53.
TD Cowen analyst Tyler Van Buren downgrades Soleno Therapeutics (NASDAQ:SLNO) from Buy to Hold and lowers the price target from $85 to $53.
Wolfe Research analyst Kalpit Patel downgrades Soleno Therapeutics (NASDAQ:SLNO) from Outperform to Peer Perform.
The Fear & Greed Index measures market sentiment with a range of 0-100, where 0 is extreme fear and 100 is extreme greed.
US stocks rose on Monday, with the Dow up 0.2%. The ISM services PMI fell to 54 in March. European shares were mostly lower, while Asian markets closed higher.